Processing

Please wait...

Settings

Settings

Goto Application

1. CA2410551 - HETERODIMERIC FUSION PROTEINS

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]
Claims
1. A heterodimeric fusion protein, comprising two chains where the first chain comprises domains that all have intrinsic affinity for a corresponding domain in the second chain, and where the heterodimerization of both chains is controlled by incorporating chosen domains that are known to constitute a preferred heterodimer.
2. A heterodimeric fusion protein as in claim 1, where the said chosen domains are selected from the CL and CH1 constant immunoglobulin domains.
3. A heterodimeric fusion protein as in claim 1 and/or 2, where the first and the second chain comprises one or more diabody chains, and form one or more functional diabodies after heterodimerization.
4. A heterodimeric fusion protein as in claim 3, where the first chain and the second chain form two distinct bispecific diabodies within the fusion protein by heterodimerization resulting in a tetraspecifc antibody derivative.
5. A heterodimeric fusion protein as in claim 3, where the first chain and the second chain form two identical bispecific diabodies within the fusion protein by heterodimerization, resulting in a bispecific antibody derivative where each said specificity is formed by a bivalent binding.
6. A heterodimeric fusion protein as in claim 3, where the first chain and the second chain form diabodies within the fusion protein by heterodimerization resulting in a recombinant antibody derivative with one bivalent binding specificity, and two other specificities.
7. A heterodimeric fusion protein as in claim 1-6, that is further extended at one or more of its N-terminal or C-terminal ends with independent folding additional protein domains, protein subunits, complete proteins, protein fragments or peptides.
8. Heterodimeric fusion proteins as in claim 1-7 for use as a medicament.
9. Use of heterodimeric fusion proteins as in claim 1-9 for the preparation of
medicament to prevent and/or treat cancer, infectious diseases, autoimmune diseases and thrombosis.
10. Use of heterodimeric fusion proteins as in claim 1-7 for use in a diagnositic kit to diagnose cancer, infectious diseases, autoimmune diseases and thrombosis.
11. One or more DNA constructs encoding the domains needed to constitute the heterodimeric fusion proteins of claim 1-7, comprising suitable transcription and translation regulatory sequences operably linked to sequences encoding the said
heterodimeric fusion proteins.
12. Method for producing heterodimeric fusion proteins as claimed in claims 1-
comprising expression of one or more DNA constructs as claimed in claim 11 in heterologous expression host cells.
13. Method as claimed in claim 12, wherein the host cells are E.coli cells, other bacterial cells, such as Bacillus spp., Lactobacillus spp. or Lactococcus spp.; actinomycetes; yeasts; filamentous fungi; mammalian cells such as COS-1 cells, HEK cells, myeloma cells or CHO cells, insect cells, transgenic animals or plants.